Novartis CEO on Tariffs, Pharma Sector Outlook, and Growth Drivers

Novartis's Financial Performance and Outlook

• 📈 Novartis reported a beat on top and bottom lines, hiking full-year guidance and increasing the buyback, despite a nearly 3% stock drop.
• 💡 The company is building US inventories to mitigate the impact of tariffs on the pharmaceutical sector.
• 🎯 Vas Narasimhan, Novartis CEO, emphasizes focusing on company fundamentals and consistent guidance raises, noting 10 consecutive quarters of improvement.

Key Growth Drivers and Franchise Performance

• 🚀 Growth drivers like the breast cancer drug Kisqali, prostate cancer drug Pluvicto, and Scemblix are performing exceptionally well, exceeding expectations.
• 💰 The company is confident in its long-run prospects due to strong financial firepower and observed performance.

Addressing Sector Concerns and Internal Changes

• ⚠️ Analysts noted weakness in Cosentix and Harry Kersh's retirement as potential negative surprises.
• 💬 Narasimhan acknowledges the need for Cosentix to regain footing but highlights its continued mid-single-digit growth and projected $8 billion medicine status.
• ✅ The retirement of CFO Harry Kersh after 13 years is considered a normal course of business for a company of Novartis's size.

Navigating the US Policy Environment

• 🗣️ Narasimhan is engaged in open discussions with the administration to find solutions regarding the US policy environment impacting the sector.
• 🔬 The goal is to balance managing patient costs and affordability with incentivizing investment in innovative medicines, particularly in light of rapid advancements in China's biotech sector.
• ⏳ A resolution on these policy topics is expected to take time, requiring the company to adapt to the ongoing situation.